Skip to main content
FluentFlash

ALL Acute Leukemia: Study Guide and Key Concepts

·

Acute leukemias are rapidly progressing blood cancers caused by uncontrolled growth of immature blood cells called blasts. The two main types are ALL (acute lymphoblastic leukemia) and AML (acute myeloid leukemia).

Understanding pathophysiology, classification, clinical presentation, and diagnostic criteria is essential for medical students, pathology residents, and board exam preparation. This guide covers morphologic features, immunophenotyping, cytogenetics, molecular findings, and treatment considerations.

Flashcards work exceptionally well for acute leukemia because the topic requires memorizing specific criteria, prognostic markers, and classification details. Spaced repetition and active recall strengthen your ability to retrieve these facts quickly during exams.

ALL acute leukemia - study with AI flashcards and spaced repetition

Pathophysiology and Classification of Acute Leukemias

Acute leukemias arise when hematopoietic stem cells transform and proliferate uncontrollably. The defining feature is >20% blasts in bone marrow or peripheral blood according to WHO classification.

Two Main Types

ALL (acute lymphoblastic leukemia) originates from B-cell or T-cell precursors. AML (acute myeloid leukemia) arises from myeloid lineage progenitors. Both result from genetic and epigenetic alterations that disrupt cell cycle control, differentiation, and apoptosis.

Key Molecular Drivers

Common mutations include:

  • t(9;22) Philadelphia chromosome in ALL
  • t(15;17) in acute promyelocytic leukemia (APL)
  • Complex karyotypes in secondary AML

These mutations guide treatment decisions and predict prognosis.

Classification Systems

The historical FAB (French-American-British) classification divided acute leukemias by morphologic subtypes. The modern WHO classification incorporates cytogenetic and molecular abnormalities, providing superior prognostic accuracy.

You must memorize the 20% blast threshold, major ALL and AML subtypes, and common chromosomal abnormalities with their clinical outcomes.

Acute Lymphoblastic Leukemia: Morphology and Immunophenotype

ALL represents approximately 80% of acute leukemias in children but only 20% in adults. Understanding morphologic and immunophenotypic patterns is critical for diagnosis and prognosis.

Morphologic Features

ALL blasts are typically smaller than AML blasts with high nuclear-to-cytoplasmic ratios. They display fine chromatin, inconspicuous nucleoli, and scant basophilic cytoplasm.

Immunophenotyping (Flow Cytometry)

Flow cytometry is the gold standard for ALL diagnosis, revealing:

  • B-ALL: CD19, CD10, CD20 positive
  • T-ALL: CD7, CD5, CD3 positive

Precursor B-ALL subdivides into common ALL (CD10 positive, ~60% of cases), pre-B-ALL (cytoplasmic mu heavy chain positive), and not otherwise specified.

Prognostic Cytogenetic Factors

Favorable prognosis features:

  • t(12;21) with ETV6-RUNX1 fusion
  • High hyperdiploidy

Unfavorable prognosis features:

  • t(9;22) Philadelphia chromosome
  • t(4;11) with KMT2A rearrangement
  • Complex karyotype

Age is also critical: children aged 1-9 years have superior outcomes compared to infants and adolescents.

Master the immunophenotypic patterns distinguishing B-ALL from T-ALL, recognize common genetic abnormalities, and understand how these factors guide risk stratification.

Acute Myeloid Leukemia: Subtypes, Cytogenetics, and Prognosis

AML accounts for 80% of acute leukemias in adults and increases with age, presenting at a median age of 70 years. Proper cytogenetic and molecular classification is essential for treatment selection.

Morphologic Features

AML blasts are typically larger than ALL blasts with abundant cytoplasm. They may contain granules or Auer rods, which are pathognomonic for AML.

WHO Classification Subtypes

  • AML with recurrent genetic abnormalities
  • AML with myelodysplasia-related changes
  • AML not otherwise specified
  • Therapy-related AML

Major Recurrent Translocations

  • t(8;21) with RUNX1-RUNX1T1 fusion (favorable prognosis)
  • t(15;17) with PML-RARA fusion in APL (favorable prognosis with appropriate therapy)

APL is unique because it presents with severe coagulopathy and is highly curable with all-trans retinoic acid (ATRA) and arsenic trioxide therapy.

Prognostic Molecular Factors

Unfavorable prognosis:

  • Complex karyotype
  • Monosomal karyotype
  • TP53 mutations
  • FLT3-ITD (internal tandem duplication)

Favorable prognosis:

  • NPM1 mutations without FLT3-ITD
  • Biallelic CEBPA mutations

Secondary AML (from prior myelodysplastic syndrome or cytotoxic chemotherapy) carries worse prognosis than de novo AML.

Memorize major cytogenetic abnormalities, prognostic significance of FLT3-ITD, NPM1, and TP53, and how cytogenetics drive therapy selection.

Diagnostic Approach and Laboratory Methods

Diagnosis requires integrating morphologic, immunophenotypic, cytogenetic, and molecular findings. Each test provides complementary information for accurate classification and risk stratification.

Initial Workup

Complete blood count reveals anemia, thrombocytopenia, and leukocytosis with circulating blasts. Peripheral blood smear allows morphologic assessment of blast characteristics including nuclear size, chromatin pattern, nucleoli, and cytoplasmic features.

Bone Marrow Studies

Bone marrow aspiration and biopsy are essential. Aspiration provides material for cytochemical stains and flow cytometry. Biopsy assesses cellularity and morphology.

Cytochemical Staining

Myeloperoxidase (MPO) staining distinguishes myeloid from lymphoid blasts. MPO positive indicates AML while negative suggests ALL.

Flow Cytometry

Flow cytometry is the gold standard for immunophenotyping, identifying blast antigen expression patterns that define lineage and maturation stage. Look for aberrant antigen expression deviating from normal patterns.

Cytogenetic Testing

  • Conventional karyotyping detects chromosomal abnormalities
  • FISH (fluorescence in situ hybridization) provides faster results for specific translocations
  • Molecular testing detects mutations in FLT3, NPM1, TP53, and KIT
  • Next-generation sequencing (NGS) provides comprehensive mutation profiling

Biochemical Assessment

Assess tumor lysis risk through uric acid and phosphate levels before starting therapy. This prevents serious complications during treatment initiation.

Understand each diagnostic method's role, interpret flow cytometry results, and appreciate how molecular findings inform prognosis and treatment decisions.

Clinical Presentation, Complications, and Study Strategies

Acute leukemia presents with symptoms reflecting bone marrow failure and leukostasis. Recognizing these features helps with early diagnosis and appropriate management.

Clinical Presentation

Anemia causes fatigue and dyspnea. Thrombocytopenia causes bleeding and petechiae. Neutropenia predisposes to infections. Constitutional symptoms include fever, night sweats, and weight loss. Organomegaly occurs in 50-75% of cases from leukemic infiltration.

Serious Complications

Leukostasis from very high blast counts causes respiratory distress, altered mental status, and visual symptoms. DIC (disseminated intravascular coagulation) is particularly associated with APL and monocytic AML. CNS involvement occurs in 5-10% of ALL cases and requires intrathecal prophylaxis. Tumor lysis syndrome causes hyperuricemia and hyperkalemia, posing life-threatening risks.

Effective Study Strategies

Create comparison flashcards distinguishing ALL from AML morphology and immunophenotype. Memorize cytogenetic abnormalities with their prognoses using mnemonic systems.

  • Review case presentations linking clinical features to diagnostic findings
  • Practice describing morphologic features of different subtypes
  • Use active recall to retrieve prognostic factors without notes
  • Create timeline flashcards showing disease progression and survival expectations
  • Study pathology images to identify blasts, Auer rods, and specialized morphologies
  • Join study groups to discuss complex cytogenetic cases

These strategies transform overwhelming information into manageable, testable units that strengthen long-term retention.

Master Acute Leukemia with Flashcards

Create personalized flashcard decks to memorize cytogenetic abnormalities, immunophenotypic patterns, prognostic factors, and diagnostic criteria for acute lymphoblastic and myeloid leukemias. Use spaced repetition and active recall to retain complex pathology information for exams.

Create Free Flashcards

Frequently Asked Questions

What percentage of blasts defines acute leukemia versus myelodysplastic syndrome?

According to WHO classification, acute leukemia is defined by 20% or greater blasts in bone marrow or peripheral blood. Myelodysplastic syndrome is characterized by less than 20% blasts with dysplastic changes in one or more cell lines.

This 20% threshold is critical for distinguishing acute leukemia from MDS, as it guides treatment intensity and prognosis. Previous institutions used 30% as the threshold, but WHO 2016 and 2022 revisions lowered this to 20% to better capture high-grade MDS patients who progress rapidly.

Higher-grade MDS patients benefit from acute leukemia-directed therapy when they approach 20% blasts. Understanding this cutoff is essential for board examinations and clinical practice, as the diagnosis determines whether patients receive intensive chemotherapy versus supportive care.

How do you differentiate between ALL and AML using morphology and immunophenotyping?

Morphology provides rapid differentiation. ALL blasts are typically smaller with high nuclear-to-cytoplasmic ratios, fine chromatin, and scant cytoplasm. AML blasts are larger with abundant cytoplasm that may contain granules or Auer rods.

Myeloperoxidase (MPO) staining offers quick confirmation. MPO is positive in AML and negative in ALL.

Flow cytometry confirms lineage. B-ALL expresses CD19 and CD10. T-ALL expresses CD7 and CD3. AML expresses myeloid markers like CD13, CD33, CD34, and often MPO. CD34 is present in immature blasts of both types but helps assess differentiation stage.

Look for aberrant antigen expression patterns that deviate from normal maturation. In ALL, the blasts cluster on different flow plots than normal B or T cells. In AML, blasts cluster with myeloid lineage cells. This combination of morphology, staining, and immunophenotyping provides definitive differentiation.

Why is cytogenetics and molecular testing so important in acute leukemia diagnosis?

Cytogenetics and molecular testing provide essential prognostic information that guides treatment intensity and predicts survival. Without these results, clinicians cannot risk-stratify patients appropriately.

Favorable cytogenetics like t(12;21) in ALL or t(8;21) in AML indicate better prognosis and may allow reduced-intensity therapy. Unfavorable features like complex karyotype, TP53 mutations, or FLT3-ITD in AML require intensified therapy and often stem cell transplantation.

Specific translocations guide therapy selection. Philadelphia chromosome t(9;22) in ALL requires tyrosine kinase inhibitor therapy. T(15;17) APL requires ATRA and arsenic trioxide rather than standard chemotherapy.

Molecular mutations refine prognosis. NPM1 and CEBPA in AML provide independent prognostic information and help identify patients likely to benefit from specific agents. These findings are foundational to modern acute leukemia management and treatment decision-making.

What causes tumor lysis syndrome in acute leukemia and how is it prevented?

Tumor lysis syndrome (TLS) occurs when massive numbers of leukemic cells rapidly die, releasing their intracellular contents into the bloodstream. This causes hyperuricemia from nucleic acid breakdown, hyperkalemia from cell rupture, and hyperphosphatemia from phosphate release.

These electrolyte abnormalities can cause acute kidney injury, cardiac arrhythmias, and seizures. TLS is particularly common in acute leukemias with high blast burdens, especially in ALL and monocytic AML.

Prevention Strategies

  • Aggressive hydration to dilute urine and maintain urine output
  • Allopurinol or rasburicase to reduce uric acid
  • Frequent electrolyte monitoring

Rasburicase (recombinant uricase) is preferred because it directly converts uric acid to allantoin, more effectively lowering uric acid levels than allopurinol. Early recognition and management prevent serious complications and allow safe initiation of therapy.

Why are flashcards especially effective for studying acute leukemia?

Acute leukemia requires mastery of multiple classification systems, cytogenetic abnormalities, immunophenotypic patterns, and prognostic criteria. Flashcards are ideal for this type of learning.

Flashcards leverage the testing effect. Retrieving information from memory strengthens long-term retention more than passive review. Creating flashcards forces active recall of specific criteria like blast percentages, prognostic factors, and differential features between ALL and AML.

Flashcard apps enable adaptive learning, showing difficult cards more frequently. Visual learners benefit from flashcards pairing images of morphology or flow plots with diagnostic features.

For complex topics like acute leukemia, flashcards break overwhelming information into manageable, testable units. This improves retention and exam performance. Flashcards enable efficient review during limited study time, making them perfect for busy medical students and residents preparing for board examinations.